Compare Ishares Msci Brazil ETF (EWZ) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Brazil ETF vs Inovio Pharmaceuticals Inc — how do they compare? Ishares Msci Brazil ETF trades at $43.48 (market cap $11.30B), while Inovio Pharmaceuticals Inc trades at $1.1 (market cap $112.19M). The key difference: Ishares Msci Brazil ETF is far larger — about 100.7× Inovio Pharmaceuticals Inc's market cap, and Ishares Msci Brazil ETF is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ishares Msci Brazil ETF for 50 Days and Inovio Pharmaceuticals Inc for 43 Days on average.
| EWZ | INO | |
|---|---|---|
Market Cap | $11.30B | $112.19M |
Volume | 44,036,597 | 3,201,278 |
Sector | Broad Market / Factor | Health |
52-Week High | $43.00 | $2.65 |
52-Week Low | $28.79 | $0.66 |
Typical Hold Time | 50 Days | 43 Days |
Enterprise Value | — | $83.51M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWZ, the iShares MSCI Brazil ETF, trades at $43.14, up 1.82% with strong bullish momentum from moving averages but overbought RSI signals. The ETF shows unusual options activity and institutional interest, driven by Brazil's upcoming election and commodity exposure. Recent news highlights Wall Street positioning for potential policy shifts under different election outcomes, with the fund serving as a diversification tool from U.S. tech concentration.
Outlook remains election-dependent with asymmetric upside potential through call options. Risks include political volatility, U.S.-Brazil trade tensions, and currency fluctuations. The technical setup suggests near-term consolidation near pivot points while fundamentals rely on Brazil's economic policies and commodity performance.
Inovio Pharmaceuticals (INO) trades at $1.09, down 5.63% today, reflecting ongoing financial challenges with minimal revenue of $65,340 in 2025 and substantial losses. The company shows consistent negative cash flow from operations but has beaten EPS estimates in recent quarters. Technical indicators are bearish, with moving averages and oscillators signaling selling pressure. Key near-term catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, its lead candidate for recurrent respiratory papillomatosis.
The investment case hinges on FDA approval of INO-3107, with analyst consensus target at $2.75 offering significant upside. However, high burn rate, negative margins, and dependence on financing pose substantial risks. Positive regulatory outcome could drive revaluation, but failure may exacerbate financial strain. Wall Street maintains cautious optimism with 59% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ishares Msci Brazil ETF
EWZ is a country-specific ETF that tracks the Brazilian equity market. It provides exposure to large and mid-sized companies in Brazil, with a heavy focus on financials and materials, including major names like Nu Holdings, Vale, and Itaú Unibanco.
Read more on EWZ →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
